Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline.
Qian Chen, Futao Chen, Cong Long...
https://pubmed.ncbi.nlm.nih.gov/37098612/Actively Recruiting
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2024-08-20
1000
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are studying Alzheimers disease, focusing on early brain changes before symptoms become clear. The goal is to create models that can predict who might progress to mild cognitive impairment or dementia by looking at a combination of personal, cognitive, behavioral, MRI brain scans, genetic, and blood-based markers. Understanding these early changes is important since current treatments for late-stage Alzheimers are limited, and early identification may help guide future interventions. The study involves collecting detailed brain imaging using various MRI techniques along with behavioral tests, genetic testing, and plasma biomarker analysis. Participants include people without memory complaints, those with subjective memory concerns, individuals with mild cognitive impairment, and patients diagnosed with Alzheimers dementia. These groups are carefully classified based on cognitive testing and clinical assessments. The research uses advanced imaging and analytical methods to explore brain structure and function, gene interactions, and biomarker associations across different disease stages. Participants will undergo multiple assessments including MRI scans, behavioral evaluations, genetic and plasma tests at the start and during follow-up. The main outcome is analyzing the ability of these combined features to predict cognitive decline over several years. Researchers will also study how brain imaging markers relate to genetic and plasma biomarkers and cognitive or behavioral changes. The study lasts several years with assessments at baseline and annual follow-ups to monitor progression and gather comprehensive data for diagnostic and prognostic model development.
CONDITIONS
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Baseline assessment
Participants undergo multimodal magnetic resonance imaging scanning and testing of behavioral, genetic, and plasma biomarkers to assess brain alterations and biological markers related to Alzheimer's disease.
1 visit (in-person)
Duration - 3 years
Participants are observed over time to monitor cognitive decline and clinical progression using repeated assessments based on baseline multimodal biomarkers.
Assessments at Baseline, Year 1, Year 2, and Year 3
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Qian Chen, Futao Chen, Cong Long...
https://pubmed.ncbi.nlm.nih.gov/37098612/The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor